Phase 3 Lymphoma Trial, Recruiting NCT05681260 Sponsor: Children's Cancer Group, China Condition: Lymphoma
Back to Lymphoma

Phase 3 Lymphoma Trial, Recruiting

NCT05681260
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been newly diagnosed with a type of blood cancer called T-lineage lymphoblastic lymphoma (T-LBL) at Stage II, III, or IV

Who may not be able to join:

  • People who have Down syndrome or a condition that causes the immune system to not work properly from birth
  • People whose T-LBL has a specific genetic marker known as "Ph+" (Philadelphia chromosome-positive) (confirm with trial site)
  • People who have already received any chemotherapy treatment for this condition
  • People who received certain steroid medications (such as prednisone or methylprednisolone) for more than 5 days within the 7 days before starting treatment, or for more than 14 days within the 28 days before starting treatment — note that steroid use more than 28 days before starting treatment is generally permitted, and steroid inhalers or creams applied to the skin are not counted; a single dose of a medication called vincristine is also permitted

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Yi-Jin Gao, MD, Shanghai Children's Medical Center

Phone: 0086-21-38087513

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Children's Cancer Group, China
Registry
ClinicalTrials.gov
Start date
6 February 2023
Est. completion
31 December 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Event free survival for standard risk patients; Event free survival according to bone marrow MDD; Event free survival for high risk patients

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov